Bavarian Nordic A/S, a vaccine developer and manufacturer, announced the appointment of James B. Breitmeyer as its new executive vice president and the division president of its cancer vaccine division on Friday.
Breitmeyer previously served as Bavarian Nordic’s executive vice president of development and as the chief medical officer of Cadence Pharmaceuticals, Inc., between 2006 and 2012. Anders Hedegaard, the president and CEO of Bavarian Nordic, said that Breitmeyer’s executive career would serve him well in the cancer vaccine division.
“We are pleased to welcome Dr. Breitmeyer to our executive management team,” Hedegaard said. “We believe that his long executive career in the pharmaceutical industry combined with his solid oncology expertise will provide the perfect leadership for our cancer vaccine division. He will apply more than two decades of clinical development experience from research through commercialization to the advancement of our cancer immunotherapy candidates, in particular PROSTVAC, which is currently in Phase III development.”
Breitmeyer said that he looked forward to facilitating the development of PROSTVAC.
“I am very enthusiastic about joining Bavarian Nordic at this exciting time,” Breitmeyer said. “Immunotherapy of cancer is a career-long interest of mine, and I believe PROSTVAC represents a state-of-the art approach, and a potentially improved treatment for patients suffering from advanced prostate cancer. I am looking forward to leading the development of this promising product candidate successfully through Phase III on its path towards commercialization.”
Breitmeyer has also served as the chief medical officer of the Eli Lilly and Co.-owned subsidiary Applied Molecular Evolution, Inc., the chief medical officer of Serono Laboratories, Inc., and as a scientific advisor to Immunogen, Inc.
Breitmeyer received his M.D. and Ph.D. from Washington University School of Medicine.